Hepatocellular Carcinoma (HCC) — Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
Citation(s)
RATIONALE-301: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma